APC and GO’SC declare payments from AstraZeneca to the National Cancer Institute (NCI) for various clinical trials. PLW receives research support from the Center for Cancer Research, NCI, National Institutes of Health (NIH) Intramural Research Program (ZID BC 011517); has worked on the KOMET trial as an official duty activity; and declares grant fundings paid to her institution from the Neurofibromatosis Therapeutic Acceleration Program and Children's Tumor Foundation. PW received consultation fees from Alexion, AstraZeneca Rare Disease, AstraZeneca, and SpringWorks Therapeutics. The contributions of NIH author, PLW, are considered works of the US Government. The findings and conclusions presented in this Correspondence are those of the authors and do not necessarily reflect the views of the NIH or the US Department of Health and Human Services. We thank Jen Shepherd of Helix, OPEN Health Communications, UK, for providing medical writing assistance, funded by Alexion, AstraZeneca Rare Disease, and Merck Sharp & Dohme, a subsidiary of Merck, Rahway, NJ, USA, under the direction of the authors and in accordance with Good Publications Practice (2022) guidelines.